Immunomodulatory Effects of LSI312A on Dendritic Cells: A Novel Approach to Modulating Inflammatory Pathways

Area of Science:

• Immunology
• Pharmacology
• Cell Biology

Background:

• Inflammation is central to many diseases, driving the need for new anti-inflammatory therapies.
• Dendritic cells (DCs) are crucial immune regulators, making them targets for immunomodulation.
• Novel compounds derived from medicinal plants offer potential therapeutic avenues.

Purpose of the Study:

• To investigate the immunomodulatory effects of LSI312A on dendritic cell (DC) function.
• To elucidate the impact of LSI312A on inflammatory signaling pathways.
• To assess the potential of LSI312A as a therapeutic candidate for inflammation.

Main Methods:

• Assessed cytotoxicity of LSI312A in DC2.4 cells.
• Measured antigen uptake and co-stimulatory molecule expression (MHC class II, CD40) after LPS stimulation.
• Quantified pro-inflammatory cytokine (TNF-α, IL-6) and nitric oxide (NO) production.
• Analyzed iNOS, NF-κB, Nrf2, and PI3K/Akt pathway activation at mRNA and protein levels.

Main Results:

• LSI312A demonstrated no cytotoxicity up to 20 μM.
• LSI312A reduced DC antigen uptake and suppressed MHC class II and CD40 expression.
• LSI312A inhibited pro-inflammatory cytokine secretion (TNF-α, IL-6) and NO production.
• LSI312A downregulated iNOS, inhibited NF-κB phosphorylation, promoted Nrf2 translocation, and suppressed PI3K/Akt activation.

Conclusions:

• LSI312A effectively modulates DC function and key inflammatory pathways.
• LSI312A exhibits significant anti-inflammatory properties by targeting NF-κB and PI3K/Akt signaling.
• LSI312A represents a promising therapeutic candidate for treating inflammation-related diseases.